Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase II for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis). According to GlobalData, Phase II drugs for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Povetacicept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Povetacicept overview
Povetacicept is under development for the treatment of myasthenia gravis, systemic lupus erythematosus, membranous glomerulonephritis, Sjogren's syndrome, proteinuria in IgA nephropathy (Berger's Disease), lupus nephritis, immune thrombocytopenia, acquired (autoimmune) hemolytic anemia, cold agglutinin disease, unspecified antibody-related neurological diseases, ANCA-associated vasculitides and autoimmune encephalitis (post-infectious). It is administered through intravenous and subcutaneous route. The drug candidate is an engineered B-cell modulator. It acts by targeting BAFF and APRIL.
It was also under development for pemphigus foliaceus, pemphigus vulgaris and bullous pemphigoid.
Alpine Immune Sciences overview
Alpine Immune Sciences (Alpine), a subsidiary of Vertex Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that discovers and develops protein-based immunotherapies. The company’s main activities involve the use of unique protein engineering strategies, including the directed evolution of immune proteins into novel, multi-targeted therapeutics. Alpine’s pipeline products include povetacicept (ALPN-303) is a dual antagonist of the B cell activating factor (BAFF) and a proliferation-inducing ligand that targets systemic lupus erythematosus, glomerulonephritis and cytopenia; and acazicolcept (ALPN-101) is a first-in-class, dual inhibitor of the CD28 and ICOS T-cell costimulatory pathways that treat systemic lupus erythematosus (SLE). Alpine is headquartered in Seattle, Washington, the US.
For a complete picture of Povetacicept’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
